Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00094445
Status:
COMPLETED
Last Update Posted:
2020-08-28
First Post:
2004-10-18
Brief Title:
Trial of Curcumin in Advanced Pancreatic Cancer
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
Phase II Trial of Curcumin in Patients With Advanced Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2020-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical research study is to learn if treatment with curcumin can help shrink or slow the growth of pancreatic cancers The effect of curcumin on the way pancreatic cancer cells function and the safety of treatment with curcumin will also be studied
Detailed Description:
Curcumin a yellow substance extracted from the plant Curcuma longa is commonly used as a food additive It is a natural anti-inflammatory compound and has shown anti-tumor activity in the laboratory During this study you will receive much higher doses of curcumin than can be obtained from the diet
During the study you will receive curcumin by mouth every day You will be required to take up to 16 pills per day each morning Every 8-week period you take curcumin is considered a course of treatment The number of courses you receive depends on how you are responding to treatment You can continue treatment as long as the disease does not get worse If the disease gets worse or you experience any intolerable side effects you will be taken off the study and your doctor will discuss other treatment options with you
You will be given a questionnaire to complete at the beginning of the study and once a week while you are on therapy to help the medical staff understand how the different symptoms from your disease are affecting you This questionnaire which should take about 5 minutes to complete can be done over the telephone or with the help of one of the study staff during your visits
At the end of each course of treatment every 8 weeks you will have a physical exam and the tumor will be re-evaluated using CT scans andor blood about 2 tablespoons tests
This is an investigational study Curcumin is a commercially available substance which is commonly used as a food additive Up to 50 participants will take part in this study All will be enrolled at M D Anderson
During the study you will receive curcumin by mouth every day You will be required to take up to 16 pills per day each morning Every 8-week period you take curcumin is considered a course of treatment The number of courses you receive depends on how you are responding to treatment You can continue treatment as long as the disease does not get worse If the disease gets worse or you experience any intolerable side effects you will be taken off the study and your doctor will discuss other treatment options with you
You will be given a questionnaire to complete at the beginning of the study and once a week while you are on therapy to help the medical staff understand how the different symptoms from your disease are affecting you This questionnaire which should take about 5 minutes to complete can be done over the telephone or with the help of one of the study staff during your visits
At the end of each course of treatment every 8 weeks you will have a physical exam and the tumor will be re-evaluated using CT scans andor blood about 2 tablespoons tests
This is an investigational study Curcumin is a commercially available substance which is commonly used as a food additive Up to 50 participants will take part in this study All will be enrolled at M D Anderson
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1R21CA104337 | NIH | None | None |
| NCI-2012-01309 | REGISTRY | NCI CTRP | httpsreporternihgovquickSearch1R21CA104337 |